Vitaspring Biomedical Return on Equity (ROE) Growth & History (VSBC)
Vitaspring Biomedical's return on equity was 108.68% for fiscal 2022.
View full Vitaspring Biomedical company overviewVitaspring Biomedical annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2022 | 2022-01-31 | 108.68% | −774.19 pp |
| 2021 | 2021-01-31 | 882.86% | — |
Vitaspring Biomedical quarterly return on equity
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q3 2023 | 2022-10-31 | −7.98% | −138.89 pp |
| Q2 2023 | 2022-07-31 | −7.85% | +43.96 pp |
| Q1 2023 | 2022-04-30 | 15.95% | −85.74 pp |
| Q4 2022 | 2022-01-31 | 16.64% | −6027.33 pp |
| Q3 2022 | 2021-10-31 | 130.91% | — |
| Q2 2022 | 2021-07-31 | −51.81% | — |
| Q1 2022 | 2021-04-30 | 101.69% | — |
| Q4 2021 | 2021-01-31 | 6,043.97% | — |
| Q3 2018 | 2017-10-31 | −36.96% | — |
| Q2 2018 | 2017-07-31 | −64.16% | — |
Vitaspring Biomedical return on equity trends
Between the periods ended 2021-01-31 and 2022-01-31, Vitaspring Biomedical's return on equity decreased from 882.86% to 108.68%, a change of −774.19 percentage points. The latest reported quarter, Q3 2023, shows −7.98%.
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Vitaspring Biomedical source filings ↗